We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

The End of End-Point Assays

The End of End-Point Assays

The determination of accurate kinetics, affinity, titer, and other critical quality attributes plays an increasingly important role in both the up-stream and down-stream processing of biopharmaceuticals.  However, the identification, isolation and characterization of potential therapeutic targets requires complex processes and analytical techniques.

Modern label-free and plate-based analytical techniques such as bio-layer interferometry (BLI) ensures that assay workflows remain quick and effective, offering reliable and robust results. 

This whitepaper highlights the recent developments and performance of three modular benchtop solutions for the high-performance quantitation and kinetics characterization of proteins and their small molecule interactions. 

Download this whitepaper to learn more about:

  • The importance of high-throughput target screening in drug development pipelines
  • How BLI technology can circumvent the limitations of ELISA and HPLC platforms
  • Solutions to accelerate cell line development, affinity assays and kinetics characterization

Brought to you by
Download the Whitepaper for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.